Lyell Immunopharma, Inc.
400 E Jamie Ct #301
South San Francisco
8 articles with Lyell Immunopharma, Inc.
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
Lyell Immunopharma announced this week that it has completed construction of a $65 million, 70,000-square-foot LyFE Manufacturing Center, which the company will use to support clinical trials and meet cell therapy manufacturing needs.
Lyell Immunopharma, Inc. (Lyell), an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, today announced the completion of its $65 million LyFE Manufacturing Center in Bothell, Washington.
Lyell Immunopharma, Inc., an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, announced the appointment of Richard Sherry, M.D., as Senior Vice President, TIL Specialist and Clinical Lead.
2/12/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Lyell Immunopharma ("Lyell"), an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, today announced the appointment of Charlie Newton as Chief Financial Officer.
Orca Bio and Lyell Immunopharma today announced a research partnership to jointly identify next generation T cell therapies that will combine precision purification T cell technologies from Orca Bio with the scientific expertise in T cell biology from Lyell
Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-Cell Therapies
Sarah Cannon, the Cancer Institute of HCA Healthcare, and Lyell Immunopharma announced a strategic collaboration for the advancement of oncology-focused immune-effector, or T-Cell, therapies.